Taiyen Biotech Co (TPE:1737) EBIT: NT$497 Mil (TTM As of Dec. 2025)


TPE:1737 Taiyen Biotech Co Ltd TPE:1737
83 GF Score
Price NT$31.90
GF Value NT$32.09
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Taiyen Biotech Co EBIT?

Taiyen Biotech Co TPE:1737 83 EBIT is NT$497 Mil as of Dec. 2025. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$32.09 (Fairly Valued). The stock has 1 warning sign investors should review.

Taiyen Biotech Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$169 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$497 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Taiyen Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 was 5.11%. Taiyen Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 16.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Taiyen Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 10.24%.


Taiyen Biotech Co  (TPE:1737) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Taiyen Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=355.124 * ( 1 - 14.94% )/( (5929.654 + 5898.119)/ 2 )
=302.0684744/5913.8865
=5.11 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8201.101 - 596.253 - ( 1675.194 - max(0, 1034.632 - 2717.339+1675.194))
=5929.654

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8262.561 - 618.67 - ( 1745.772 - max(0, 959.885 - 2756.224+1745.772))
=5898.119

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Taiyen Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=675.82/( ( (4087.599 + max(-86.104, 0)) + (4119.045 + max(-78.978, 0)) )/ 2 )
=675.82/( ( 4087.599 + 4119.045 )/ 2 )
=675.82/4103.322
=16.47 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(173.583 + 412.669 + 117.953) - (596.253 + 0 + 194.056)
=-86.104

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(197.844 + 376.805 + 109.618) - (618.67 + 0 + 144.575)
=-78.978

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Taiyen Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=497.347/4857.431
=10.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiyen Biotech Co EBIT Related Terms


Taiyen Biotech Co EBIT Historical Data

* Premium members only.

The historical data trend for Taiyen Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co EBIT Chart

Taiyen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 515.86 535.11 332.47 439.37 497.35

Taiyen Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.97 118.86 110.41 99.12 168.96

TPE:1737 vs PG, CL, KVUE: EBIT Comparison

For the Household & Personal Products subindustry, Taiyen Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiyen Biotech Co EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taiyen Biotech Co's EV-to-EBIT falls into.


TPE:1737
83GF Score
Taiyen Biotech Co Ltd TPE:1737
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiyen Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$497 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$497 Mil mean?
Taiyen Biotech Co (TPE:1737) has a EBIT of NT$497 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Taiyen Biotech Co.
Is Taiyen Biotech Co's EBIT too high?
Taiyen Biotech Co's current EBIT is NT$497 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's EBIT compare to PG and CL?
Taiyen Biotech Co's EBIT of NT$497 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Taiyen Biotech Co. Taiyen Biotech Co's current EBIT is NT$497 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.09, compared to a current price of NT$31.90 — trading 0.6% below its estimated fair value. The current EBIT is NT$497 Mil. Taiyen Biotech Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current EBIT is NT$497 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?

Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued. The current stock price of NT$31.90 is trading 0.6% below its estimated GF Value™ of NT$32.09. GuruFocus considers Taiyen Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1737:

  • EBIT: NT$497 Mil
  • GF Value™: NT$32.09 vs. price of NT$31.90 (0.6% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taiyen Biotech Co Business Description

Address No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score

Get the complete analysis for TPE:1737

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.90
Price
NT$32.09
GF Value